-
Mashup Score: 0Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC - 13 day(s) ago
Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 1Efforts to Yield Greater OS Benefit With EGFR TKIs Continue in Early-Stage EGFR+ NSCLC - 13 day(s) ago
Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Efforts to Yield Greater OS Benefit With EGFR TKIs Continue in Early-Stage EGFR+ NSCLC @gotoPER #ILCC2025 #lcsm https://t.co/L57RwPqGfg
-
-
Mashup Score: 1
Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC @marinagarassino @gotoPER #ILCC2025 #lcsm https://t.co/c8m2G8NK1t
-
-
Mashup Score: 3High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC - 16 day(s) ago
Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC @LudaBazhenovaMD @UCSDCancer @gotoPER #ILCC2025 #lcsm https://t.co/xVSO2OqV4A
-
Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC @gotoPER #ILCC2025 #lcsm https://t.co/GxrsbXxAP9